OBJECTIVE:To probe into the clinical efficacy and adverse drug reaction of amoxycillin /clavulanate potassium combined with conventional anti-TB drugs in treatment of multidrug resistance tuberculosis ( MDR-TB ) . METHODS:205 MDR-TB patients were divided into treatment group (103 patients) and control group (102 patients) by random number table .The control group was given amoxycillin , ethambutol , isoniazid aminosalicylate , rifapentine and levofloxacin , the observation group received amoxycillin/clavulanate potassiumthe based on the same treatment regimen of the control group .The treatment course of 2 groups was 12 months.The changes of sputum negative conversion, focal absorption, cavity, the improved clinical symptoms and negative ADR consequences were closely observed in two groups .RESULTS:After the treatment of 3 months, there was no statistically significant difference of the sputum negative conversion rate in 2 groups ( P>0.05 ) .In the treatment group , the sputum negative rate at the sixth, ninth and twelfth month were respectively 68.93%(71/103), 74.76%(77/103) and 81.55%(84/103), which was significantly higher than that in the control group 50.98%( 52/102 )、55.88%( 57/102 ) and 60.78%(62/102) respectively, with statistically significant difference ( P >0.05).At the end of the treatment, the focal absorption rate of treatment group and control group was respectively 88.35%(91/103) and 66.67%(68/102), the cavity closure rate of treatment group and control group were respectively 84.47%(87/103) and 64.71%(66/102);the above-mentioned indexes in the treatment group were all significantly better than that in the control group , with significant difference ( P<0.05 ) .CONCLUSIONS:It is safe and effective to use amoxycillin/clavulanate potassium in the treatment of MDR-TB, but still have few significant advantages in the short-term efficacy.%目的：探讨阿莫西林／克拉维酸钾联合常规抗结核药治疗耐多药肺结核（ multidrug resistance tuberculosis ，MDR-TB）的临床疗效和不良反应。方法：将205例MDR-TB患者按随机数字表法分为观察组103例和对照组102例。对照组患者给予吡嗪酰胺、乙胺丁醇、对氨基水杨酸异烟肼、利福喷丁和左氧氟沙星，观察组患者在对照组治疗的基础上加用阿莫西林／克拉维酸钾，2组疗程均为12个月。观察患者的痰菌阴转、病灶吸收、空洞闭合和不良反应发生情况。结果：治疗3个月后，2组患者痰菌阴转率的差异无统计学意义（P＞0.05）；治疗6、9、12个月后，观察组患者痰菌阴转率分别为68.93％（71／103）、74.76％（77／103）和81.55％（84／103），均明显高于对照组的50.98％（52／102）、55.88％（57／102）和60.78％（62／102），差异有统计学意义（P＜0.05）；疗程结束时观察组与对照组患者的病灶吸收总有效率分别为88.35％（91／103）和66.67％（68／102），空洞闭合总有效率分别为84.47％（87／103）和64.71％（66／102），观察组均明显优于对照组，差异均有统计学意义（P＜0.05）。结论：阿莫西林／克拉维酸钾联合常规抗结核药治疗MDR-TB安全、有效，但短期疗效优势不明显。
展开▼
